Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740799 | 0.84 | ADORA1 (0.60) | ADORA1ADORA2AHSD17B10SMN1; SMN2HTT | |
| SCHEMBL20570608 | 0.83 | KMT2A (0.67) | ADORA1ADORA2AHSD17B10SMN1; SMN2HTT | |
| SCHEMBL3369656 | 0.76 | ADORA1 (0.83) | ADORA1ADORA2AHSD17B10HTTALDH1A1 | |
| SCHEMBL19885514 | 0.76 | HTT (0.54) | ADORA1ADORA2AHSD17B10SMN1; SMN2HTT | |
| SCHEMBL19885511 | 0.75 | HTT (0.53) | ADORA1ADORA2AHSD17B10SMN1; SMN2HTT | |
| SCHEMBL3370624 | 0.73 | ADORA1 (0.76) | ADORA1ADORA2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL30272734 | 0.72 | HIF1A (0.68) | SMN1; SMN2HTTLMNAKDM4EKMT2A | |
| SCHEMBL149565 | 0.72 | HIF1A (0.68) | SMN1; SMN2HTTLMNAKDM4EKMT2A | |
| SCHEMBL25774104 | 0.72 | SMN1; SMN2 (0.50) | ADORA1ADORA2AHSD17B10SMN1; SMN2HTT | |
| SCHEMBL15452668 | 0.72 | ALDH1A1 (0.66) | ADORA1ADORA2ASMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124649-A1 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124649-A1 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124649-A1 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2009064388-A2 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | LIU JUN O (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064388-A2 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | LIU JUN O (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124649-A1 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | METAP1, DNPEP, METAP2 | ADORA1 333/4885ADORA2A 546/4885HSD17B10 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.